<DOC>
	<DOCNO>NCT01034566</DOCNO>
	<brief_summary>RATIONALE : Specialized radiation therapy , proton beam radiation therapy , delivers high dose radiation directly tumor may kill tumor cell cause less damage normal tissue patient retroperitoneal sarcoma . PURPOSE : This phase I trial study side effect best dose proton beam radiation therapy treat patient retroperitoneal sarcoma .</brief_summary>
	<brief_title>Proton Beam Radiation Therapy Treating Patients With Retroperitoneal Sarcoma</brief_title>
	<detailed_description>Detailed DescriptionPRIMARY OBJECTIVES : I . To determine feasibility toxicity proton radiotherapy retroperitoneal sarcoma . II . To determine maximum safe proton radiotherapy dose retroperitoneal sarcoma . III . To determine maximally tolerate dose proton radiotherapy patient potentially resectable retroperitoneal sarcoma . ( Pre-operative cohort ) IV . To assess acute side effect irradiation use proton beam therapy dose/volume constraint derive conventional radiotherapy . ( Postoperative cohort ) SECONDARY OBJECTIVES : I . To assess clinical effectiveness proton radiotherapy retroperitoneal sarcoma . II . To determine long-term toxicity proton radiotherapy abdomen pelvis region . III . To monitor effect proton treatment tumor normal tissue use radiographic imaging ( cohort ) ex-vivo analysis tissue sample ( preoperative cohort ) .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<criteria>Patients histologic diagnosis sarcoma peritoneum/retroperitoneum/pelvis eligible study Patients must either radiographic ( preoperative ) pathologic ( postoperative ) evidence disease limit peritoneum/retroperitoneum/pelvis without evidence peritoneal sarcomatosis For preoperative case , patient must consider operable/resectable judged attend surgeon ( determined extensive radiographic medical evaluation include limited : CT Chest Abdomen contrast , MRI/CT Brain Medical/Cardiac Clearance ) Patients EGOC status 02 Patients must sign document indicate aware investigative nature treatment protocol , potential benefit risk ( patient unwilling unable sign inform consent exclude study ) Women childbearing potential long agree use recognize method birth control ( e.g . oral contraceptive , IUD , condom barrier method etc . ) ; hysterectomy menopause must clinically document Prior simultaneous malignancy within past two year ( cutaneous squamous basal cell carcinoma , melanoma situ thyroid carcinoma ) Pregnant woman , woman plan become pregnant woman nurse Patients experience surgical complication prevent radiation start 5 month , unless evidence gross residual disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>